Literature DB >> 9892014

C-terminal region of human somatostatin receptor 5 is required for induction of Rb and G1 cell cycle arrest.

K Sharma1, Y C Patel, C B Srikant.   

Abstract

Ligand-activated somatostatin receptors (SSTRs) initiate cytotoxic or cytostatic antiproliferative signals. We have previously shown that cytotoxicity leading to apoptosis was signaled solely via human (h) SSTR subtype 3, whereas the other four hSSTR subtypes initiated a cytostatic response that led to growth inhibition. In the present study we characterized the antiproliferative signaling mediated by hSSTR subtypes 1, 2, 4, and 5 in CHO-K1 cells. We report here that cytostatic signaling via these subtypes results in induction of the retinoblastoma protein Rb and G1 cell cycle arrest. Immunoblot analysis revealed an increase in hypophosphorylated form of Rb in agonist-treated cells. The relative efficacy of these receptors to initiate cytostatic signaling was hSSTR5 > hSSTR2 > hSSTR4 approximately = hSSTR1. Cytostatic signaling via hSSTR5 also induced a marginal increase in cyclin-dependent kinase inhibitor p21. hSSTR5-initiated cytostatic signaling was G protein dependent and protein tyrosine phosphatase (PTP) mediated. Octreotide treatment induced a translocation of cytosolic PTP to the membrane, whereas it did not stimulate PTP activity when added directly to the cell membranes. C-tail truncation mutants of hSSTR5 displayed progressive loss of antiproliferative signaling proportional to the length of deletion, as reflected by the marked decrease in the effects of octreotide on membrane translocation of cytosolic PTP, and induction of Rb and G1 arrest. These data demonstrate that the C-terminal domain of hSSTR5 is required for cytostatic signaling that is PTP dependent and leads to induction of hypophosphorylated Rb and G1 arrest.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9892014     DOI: 10.1210/mend.13.1.0220

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  16 in total

1.  Nuclear medicine in the treatment of neuroendocrine tumours--problems and perspectives.

Authors:  Tomasz Grzela; Agata Bialoszewska; Robert Brawura-Biskupski-Samaha
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-04       Impact factor: 9.236

2.  An enteroendocrine cell-based model for a quiescent intestinal stem cell niche.

Authors:  I R Radford; P N Lobachevsky
Journal:  Cell Prolif       Date:  2006-10       Impact factor: 6.831

3.  Characterization of intracellular signaling mediated by human somatostatin receptor 5: role of the DRY motif and the third intracellular loop.

Authors:  Erika Peverelli; Andrea G Lania; Giovanna Mantovani; Paolo Beck-Peccoz; Anna Spada
Journal:  Endocrinology       Date:  2009-04-02       Impact factor: 4.736

4.  Identification of human somatostatin receptor 2 domains involved in internalization and signaling in QGP-1 pancreatic neuroendocrine tumor cell line.

Authors:  Valeria Cambiaghi; Eleonora Vitali; Diego Morone; Erika Peverelli; Anna Spada; Giovanna Mantovani; Andrea Gerardo Lania
Journal:  Endocrine       Date:  2016-07-12       Impact factor: 3.633

5.  Somatostatin receptor (SSTR) expression and function in normal and leukaemic T-cells. Evidence for selective effects on adhesion to extracellular matrix components via SSTR2 and/or 3.

Authors:  T Talme; J Ivanoff; M Hägglund; R J Van Neerven; A Ivanoff; K G Sundqvist
Journal:  Clin Exp Immunol       Date:  2001-07       Impact factor: 4.330

6.  Loss of heterozygosity at the SS receptor type 5 locus in human GH- and TSH-secreting pituitary adenomas.

Authors:  M Filopanti; E Ballarè; A G Lania; S Bondioni; U Verga; M Locatelli; L M Zavanone; M Losa; S Gelmini; A Peri; C Orlando; P Beck-Peccoz; A Spada
Journal:  J Endocrinol Invest       Date:  2004-11       Impact factor: 4.256

Review 7.  Treatment of pituitary tumors: somatostatin.

Authors:  Maria A Tichomirowa; Adrian F Daly; Albert Beckers
Journal:  Endocrine       Date:  2005-10       Impact factor: 3.633

Review 8.  Somatostatin and somatostatin receptor physiology.

Authors:  Philip Barnett
Journal:  Endocrine       Date:  2003-04       Impact factor: 3.633

9.  Antiproliferative and proapoptotic effects of somatostatin on activated hepatic stellate cells.

Authors:  Qin Pan; Ding-Guo Li; Han-Ming Lu; Liang-Yong Lu; Yu-Qin Wang; Qin-Fang Xu
Journal:  World J Gastroenterol       Date:  2004-04-01       Impact factor: 5.742

10.  The immunohistochemical localisation of somatostatin receptors 1, 2, 3, and 5 in acoustic neuromas.

Authors:  N D Stafford; L T Condon; M J C Rogers; L Helboe; D A Crooks; S L Atkin
Journal:  J Clin Pathol       Date:  2004-02       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.